![Manual Voltage Clamp of Cardiac Ion Currents
INa
I/V Diagram
(Normalized to Maximum Amplitude)
0
-70 -50 -30 -10 10 30 50 70
-0,2
Normalized current
-0,4
-0,6
-0,8
-1
-1,2
voltage [mV]](https://image.slidesharecdn.com/090630ioncannelretreat-12526693425926-phpapp02/85/090630-Ion-Cannel-Retreat-31-320.jpg)
![Manual Voltage Clamp of Cardiac Ion Currents
INa ICa
I/V Diagram I/V Diagram
(Normalized to Maximum Amplitude) (Normalized to Maximum Amplitude)
0 0
-70 -50 -30 -10 10 30 50 70 -70 -50 -30 -10 10 30 50 70
-0,2 -0,2
Normalized current
Normalized current
-0,4 -0,4
-0,6
-0,6
-0,8
-0,8
-1
-1
-1,2
-1,2
voltage [mV] voltage [mV]](https://image.slidesharecdn.com/090630ioncannelretreat-12526693425926-phpapp02/85/090630-Ion-Cannel-Retreat-32-320.jpg)
![Manual Voltage Clamp of Cardiac Ion Currents
INa ICa IK
I/V Diagram I/V Diagram I/V Diagram
(Normalized to Maximum Amplitude) (Normalized to Maximum Amplitude) (Normalized to Maximum Amplitude)
1,2
0 0
-70 -50 -30 -10 10 30 50 70 -70 -50 -30 -10 10 30 50 70
1
Normalized current
-0,2 -0,2
Normalized current
Normalized current
0,8
-0,4 -0,4
0,6
-0,6
-0,6
0,4
-0,8
-0,8
0,2
-1
-1
0
-1,2
-1,2 -60 -40 -20 0 20 40 60 80
voltage [mV] voltage [mV] voltage [mV]](https://image.slidesharecdn.com/090630ioncannelretreat-12526693425926-phpapp02/85/090630-Ion-Cannel-Retreat-33-320.jpg)
![Seminario molecular[1] listo](https://cdn.slidesharecdn.com/ss_thumbnails/seminariomolecular1listo-110302234433-phpapp02-thumbnail.jpg?width=640&height=640&fit=bounds)
090630 Ion Cannel Retreat
- 1. Pluripotent Stem Cell-derived Cardiomyocytes as Suitable Substrates For Automated Ion Channel and Electrophysiological Analysis Systems Dr. Ralf Kettenhofen Axiogenesis AG 7th Ion Channel Retreat June 29th, Vancouver
- 2.
- 3. Content Introduction Transgenic Pluripotent Stem Cells Selection of Cardiomyocytes from Differentiated mouse ES Cells
- 4. Content Introduction Transgenic Pluripotent Stem Cells Selection of Cardiomyocytes from Differentiated mouse ES Cells Automated Recording and Pharmacology of Cardiac Ion Currents
- 5. Content Introduction Transgenic Pluripotent Stem Cells Selection of Cardiomyocytes from Differentiated mouse ES Cells Automated Recording and Pharmacology of Cardiac Ion Currents Automated Recording and Pharmacology of Cardiac Action Potentials
- 6. Content Introduction Transgenic Pluripotent Stem Cells Selection of Cardiomyocytes from Differentiated mouse ES Cells Automated Recording and Pharmacology of Cardiac Ion Currents Automated Recording and Pharmacology of Cardiac Action Potentials Automated Analyses and Pharmacology of Cardiac Na+/K+-ATPases
- 7. Content Introduction Transgenic Pluripotent Stem Cells Selection of Cardiomyocytes from Differentiated mouse ES Cells Automated Recording and Pharmacology of Cardiac Ion Currents Automated Recording and Pharmacology of Cardiac Action Potentials Automated Analyses and Pharmacology of Cardiac Na+/K+-ATPases Summary
- 8. Content Introduction Transgenic Pluripotent Stem Cells Selection of Cardiomyocytes from Differentiated mouse ES Cells Automated Recording and Pharmacology of Cardiac Ion Currents Automated Recording and Pharmacology of Cardiac Action Potentials Automated Analyses and Pharmacology of Cardiac Na+/K+-ATPases Summary Conclusion
- 9. The Optimal CellularModel
- 10. The Optimal CellularModel Physiological properties
- 11. The Optimal CellularModel Physiological properties Ready-to-use availability
- 12. The Optimal CellularModel Physiological properties Ready-to-use availability Lot-to-lot reproducibility
- 13. The Optimal CellularModel Physiological properties Ready-to-use availability Lot-to-lot reproducibility No inter lab-differences
- 14. The Optimal CellularModel Physiological properties Ready-to-use availability Lot-to-lot reproducibility No inter lab-differences Purity
- 15. The Optimal CellularModel Physiological properties Ready-to-use availability Lot-to-lot reproducibility No inter lab-differences Purity Relevant and predictive
- 16. The Optimal CellularModel Physiological properties Ready-to-use availability Lot-to-lot reproducibility No inter lab-differences Purity Relevant and predictive
- 17. Puromycin Selection ofCardiomyocytes from Genetically Engineered Embryonic Stem Cells
- 18. Puromycin Selection ofCardiomyocytes from Genetically Engineered Embryonic Stem Cells
- 19. Puromycin Selection ofCardiomyocytes from Genetically Engineered Embryonic Stem Cells Differentiation of ES cells and selection of cardiomyocytes
- 20. Puromycin Selection ofCardiomyocytes from Genetically Engineered Embryonic Stem Cells Differentiation of ES cells and selection of cardiomyocytes 9d Puro 0d
- 21. Puromycin Selection ofCardiomyocytes from Genetically Engineered Embryonic Stem Cells Differentiation of ES cells and selection of cardiomyocytes 9d 10d 12d Puro 0d Puro 1d Puro 3d
- 22. Puromycin Selection ofCardiomyocytes from Genetically Engineered Embryonic Stem Cells Differentiation of ES cells and selection of cardiomyocytes 9d 10d 12d Puro 0d Puro 1d Puro 3d Quality control Freezing Dissociation
- 23. Puromycin Selection ofCardiomyocytes from Genetically Engineered Embryonic Stem Cells Differentiation of ES cells and selection of cardiomyocytes 9d 10d 12d Puro 0d Puro 1d Puro 3d Quality control Freezing Dissociation
- 24. Specificity and InVivo Relevance?
- 25. Specificity and InVivo Relevance? Fleischmann M. et al. FEBS Lett. 1998 Dec 4;440(3):370-6
- 26. Specificity and InVivo Relevance? Kolossov E. J Exp Med. 2006 Oct 2;203(10):2315-27. Fleischmann M. et al. FEBS Lett. 1998 Dec 4;440(3):370-6
- 27. ES Cell-derived, GeneticallySelected and Purified Cardiomyocytes 17d in culture after thawing
- 28. ES Cell-derived, GeneticallySelected and Purified Cardiomyocytes 17d in culture after thawing Frozen ES cell-derived and purfied cardiomyocytes are viable and retain their autonomous contractile phenotype for at least 3 weeks after thawing when cultured in monolayer.
- 29. Gene Expression Analysis P =Present A = Absent Cor.At Cardiomyocytes Cor.At Cardiomyocytes Gene symbol days in culture after thawing Protein Gene symbol days in culture after thawing Protein 2d 20d 2d 20d SCN5a P P Nav1.5 ABCC8 P P SUR1 CACNA1c P P Cav1.2 (!1c) Pias3 P P KChAP, PIAS3 CACNA1h P P Cav3.2 (!1h) AKAP6 P P AKAP 6 KCNA1 P P Kv1.1 AKAP9 P P Yotiao KCNA4 P P Kv1.4 AKAP10 P P D-AKAP2 KCNA5 P A Kv1.5 AKAP12 P P Gravin KCNA7 P P Kv1.7 AKAP7 P P AKAP 7 KCNB1 P P Kv2.1 Slc8a1 P P NCX1 KCND2 A P Kv4.2 Slc12a2 P P ENCC3, BSC2, NKCC1 KCND3 P P Kv4.3 Slc9a1 P P SLC9A1, APNH, NHE1 KCNG2 P P Kv subfamily G, member 2 ATP1A1 P P Na+/K+-ATPase !1 KCNV2 A P Kv8.2 ATP1A2 P P Na+/K+-ATPase !2 KCNH2 P P erg1 (LQT2), Kv11.1 KvLQT1 (Kv7.1, JLN-1) ATP1A3 P P Na+/K+-ATPase !3 KCNQ1 P P ATP1B1 P P Na+/K+-ATPase "1 CLCN3 P P ClC-3 ATP1B2 P P Na+/K+-ATPase "2 clcn4-2 P P ClC-4 CLCN6 P P ClC-6 ATP1B3 P P Na+/K+-ATPase "3 CLCN7 P P ClC-7 ATP2A2 P P SERCA2, cardiac muscle, slow twitch 2 CLCA1 P P ClCa-1 RYR2 P P ryanodine receptor , RYR2 KCNJ12 P P Kir2.2 Ank2 P P Akyrin B (LQT-4) KCNJ3 P P Kir3.1 Gja1 P P Connexin 43 KCNJ5 P P Kir3.4 Gja3 P P Connexin 46 KCNJ6 P P Kir3.2 Gja7 P P Connexin 45 KCNJ11 P P Kir6.2 Slc4a3 P P anion exchanger 3 brain + cardiac isoforms KCNK6 P P TWIK-2 Vdac2 P P voltage-dependent anion channel 2 HCN1 P P HCN-1 Vdac1 P P voltage-dependent anion channel 1 HCN2 P P HCN-2 Pacsin2 P P Kv Shab-related subfamily, member 1 SCN1b P P SCN1B KCNN1 A P calcium-activated SK1 CACNB2 P P CACNB2 KCNN2 P P calcium-activated SK2 CACNA2d1 P P CACNA2d1 Slc24a3 P P Slc24a (Na/K/Ca exchanger), member 3 KCNE1 P P minK Slc24a6 P P Slc24a (Na/K/Ca exchanger), member 6 KCNIP2 A P KChIP2 Slc12a9 P P Slc12a (Na/K/Ca exchanger), member 9
- 30. Manual Voltage Clampof Cardiac Ion Currents
- 31. Manual Voltage Clampof Cardiac Ion Currents INa I/V Diagram (Normalized to Maximum Amplitude) 0 -70 -50 -30 -10 10 30 50 70 -0,2 Normalized current -0,4 -0,6 -0,8 -1 -1,2 voltage [mV]
- 32. Manual Voltage Clampof Cardiac Ion Currents INa ICa I/V Diagram I/V Diagram (Normalized to Maximum Amplitude) (Normalized to Maximum Amplitude) 0 0 -70 -50 -30 -10 10 30 50 70 -70 -50 -30 -10 10 30 50 70 -0,2 -0,2 Normalized current Normalized current -0,4 -0,4 -0,6 -0,6 -0,8 -0,8 -1 -1 -1,2 -1,2 voltage [mV] voltage [mV]
- 33. Manual Voltage Clampof Cardiac Ion Currents INa ICa IK I/V Diagram I/V Diagram I/V Diagram (Normalized to Maximum Amplitude) (Normalized to Maximum Amplitude) (Normalized to Maximum Amplitude) 1,2 0 0 -70 -50 -30 -10 10 30 50 70 -70 -50 -30 -10 10 30 50 70 1 Normalized current -0,2 -0,2 Normalized current Normalized current 0,8 -0,4 -0,4 0,6 -0,6 -0,6 0,4 -0,8 -0,8 0,2 -1 -1 0 -1,2 -1,2 -60 -40 -20 0 20 40 60 80 voltage [mV] voltage [mV] voltage [mV]
- 34. Manual vs. AutomatedPatch - Chip replaces Pipette Pipette: “Aperture towards the 2 µm
- 35. Manual vs. AutomatedPatch - Chip replaces Pipette Pipette: “Aperture towards the Chip: “Cell towards the 2 µm 20 µm
- 36. Prerequisites for AutomatedPatch Clamp
- 37. Prerequisites for AutomatedPatch Clamp Homogeneous cell population
- 38. Prerequisites for AutomatedPatch Clamp Homogeneous cell population No contamination with other cell types (e.g. fibroblasts)
- 39. Prerequisites for AutomatedPatch Clamp Homogeneous cell population No contamination with other cell types (e.g. fibroblasts) Round morphology
- 40. Prerequisites for AutomatedPatch Clamp Homogeneous cell population No contamination with other cell types (e.g. fibroblasts) Round morphology Relatively high amount of cells.
- 41. ® Cor.At Cardiomyocytes and PatchXpress 7000A ® MDS - Analytical Technologies
- 42. ® Cor.At Cardiomyocytes and PatchXpress 7000A ® MDS - Analytical Technologies Dr. Xin Jiang
- 43. ® PatchXpress 7000A -Cardiac Ion Currents
- 44. ® PatchXpress 7000A -Cardiac Ion Currents INa 1 nA 2 ms I/V Diagram
- 45. ® PatchXpress 7000A -Cardiac Ion Currents INa ICa 1 nA 100 pA 50 ms 2 ms I/V Diagram
- 46. ® PatchXpress 7000A -Cardiac Ion Currents INa ICa IK 1 nA 100 pA 50 ms 2 ms I/V Diagram I/V Diagram
- 47. Statistics Subject Number of cells Result ± SEM High resistance seals (> 1GΩ), (%) 96 45 ± 12 Successful whole cell (%) 96 49 ± 16 Peak INa (nA) (at -20 mV) 6 1.52 ± 0.23 Peak ICa (nA) (at +10 mV) 11 0.067 ± 0.008 Peak IK (nA) (at +20 mV) 21 0.49 ± 0.11
- 48. ® PatchXpress 7000A: PotassiumCurrent Pharmacology 4-Aminopyridine Control 10 µM
- 49. ® PatchXpress 7000A: PotassiumCurrent Pharmacology 4-Aminopyridine Control 10 µM
- 50. ® PatchXpress 7000A: ß-adrenergicmodulation of I(Ca,L)
- 51. ® PatchXpress 7000A: ß-adrenergicmodulation of I(Ca,L) Epinephrine (Adrenaline)
- 52. ® PatchXpress 7000A: ß-adrenergicmodulation of I(Ca,L) Epinephrine (Adrenaline) Epi, 10 µM
- 53. ® PatchXpress 7000A: ß-adrenergicmodulation of I(Ca,L) Epinephrine (Adrenaline) Epi, 10 µM
- 54. ® Cor.At Cardiomyocytes and QPatch ® Sophion Bioscience A/S
- 55. ® Cor.At Cardiomyocytes and QPatch ® Sophion Bioscience A/S Dr. Rikke Schrøder
- 56. ® QPatch - IonCurrents
- 57. ® QPatch - IonCurrents INa I/V Diagram
- 58. ® QPatch - IonCurrents INa ICa I/V Diagram I/V Diagram
- 59. ® QPatch - IonCurrents INa ICa IK I/V Diagram I/V Diagram I/V Diagram
- 60.
- 61. Statistics Avergage of 4QPlates 16
- 62. Statistics Subject Number of cells Result Viability after harvest procedure (%) 87± 3 Size of cell (pF) 112 17 ± 7 Cells with recordable INa amplitude (%) 15 of 22 68 Current density INa (pA/pF) 52 104 ± 129 Peak INa (pA) (at -30 mV) 52 1842 ± 2521 Cells with recordable ICa amplitude (%) 12 of 22 55 Current density ICa (pA/pF) 32 2 ± 1.5 Avergage of 4 QPlates 16 Peak ICa (nA) (at +10 mV) 32 0.035 ± 0.027
- 63. ® QPatch - SodiumCurrent Pharmacology INa block with TTX
- 64. ® QPatch - SodiumCurrent Pharmacology INa block with TTX
- 65. ® QPatch - SodiumCurrent Pharmacology INa block with TTX
- 66. ® QPatch - SodiumCurrent Pharmacology INa block with TTX A) baseline
- 67. ® QPatch - SodiumCurrent Pharmacology INa block with TTX B) 50 nM A) baseline
- 68. ® QPatch - SodiumCurrent Pharmacology INa block with TTX C) 5 µM B) 50 nM A) baseline
- 69. ® QPatch - ß-adrenergic modulation of I(Ca,L) Voltage protocol
- 70. ® QPatch - ß-adrenergicmodulation of I(Ca,L) Isoproterenol
- 71. ® QPatch - ß-adrenergicmodulation of I(Ca,L) Isoproterenol
- 72. ® QPatch - ß-adrenergicmodulation of I(Ca,L) Isoproterenol 1) baseline
- 73. ® QPatch - ß-adrenergicmodulation of I(Ca,L) Isoproterenol 1) baseline 2) 1 µM Iso
- 74. ® QPatch - ß-adrenergicmodulation of I(Ca,L) Isoproterenol 1) baseline 2) 1 µM Iso 3) 10 µM Iso
- 75. ® QPatch - ß-adrenergicmodulation of I(Ca,L) Isoproterenol 4) 10 µM Nifedipine 1) baseline 2) 1 µM Iso 3) 10 µM Iso
- 76. ® QPatch - ß-adrenergicmodulation of I(Ca,L) Isoproterenol 4) 10 µM Nifedipine 1) baseline 2) 1 µM Iso 3) 10 µM Iso
- 77. ® Cor.AtCardiomyocytes and ® Port-a-Patch and Patchliner ® Nanion Technologies
- 78. ® Cor.AtCardiomyocytes and ® Port-a-Patch and Patchliner ® Nanion Technologies Dr. Sonja Stölzle
- 79.
- 80. Voltage Clamp INa I/V Diagram
- 81. Voltage Clamp INa ICa I/V Diagram I/V Diagram
- 82. Voltage Clamp INa ICa IK I/V Diagram I/V Diagram I/V Diagram
- 83. Automated Current ClampRecording
- 84. Automated Current ClampRecording Port-a-Patch® Stimulation Protocol (500 ms stimuli at 0.2 Hz) -40 pA I(memb) 150 ms 20 mV
- 85. Automated Current ClampRecording Port-a-Patch® Patchliner ® Stimulation Protocol (500 ms stimuli at 0.2 Hz) Screen Shot from a 4 channel Patchliner -40 pA I(memb) 150 ms 20 mV
- 86. Preliminary Statistical Data Subject Result Patched Cells in 2.5 days 45 Success rate for gigaseal and whole cell (%) about 80 Cells with recordable action potentials amplitude (%) 50 Cells with recordable INa amplitude (%) 50 Cells with recordable ICa amplitude (%) 100 Cells with recordable IK amplitude (%) 60
- 87. ® Port-a-Patch - SodiumChannel Pharmacology Tetrodotoxin (TTX)
- 88. ® Port-a-Patch - SodiumChannel Pharmacology Tetrodotoxin (TTX) control TTX 20 µM 150 ms 20 mV washout
- 89. ® Patchliner - SodiumChannel Pharmacology
- 90. ® Patchliner - SodiumChannel Pharmacology min
- 91. ® Patchliner - SodiumChannel Pharmacology min
- 92. ® Port-a-Port - Identificationof hERG blocker
- 93. ® Port-a-Port - Identificationof hERG blocker Dofetilide
- 94. ® Port-a-Port - Identificationof hERG blocker Dofetilide control Dofetilide, 1µM 150 ms 20 mV 150 ms 20 mV washout
- 95. ® Patchliner - PotassiumChannel Pharmacology
- 96. ® Patchliner - PotassiumChannel Pharmacology Quinidine
- 97. ® Patchliner - PotassiumChannel Pharmacology Quinidine min stimulation interval: 0.1 Hz
- 98. ® Patchliner - PotassiumChannel Pharmacology Quinidine min stimulation interval: 0.1 Hz 150 ms
- 99. Why is itpossible to identify hERG blocker effects in mouse ES cell-derived cardiomyocytes?
- 100. Developmental Changes ofMouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 101. Developmental Changes ofMouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 102. Developmental Changes ofMouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 103. Developmental Changes ofMouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 104. Developmental Changes ofMouse Cardiac Repolarization Change of the Dofetilide Sensitivity of Mouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 105. Developmental Changes ofMouse Cardiac Repolarization Change of the Dofetilide Sensitivity of Mouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 106. Developmental Changes ofMouse Cardiac Repolarization Change of the Dofetilide Sensitivity of Mouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 107. Developmental Changes ofMouse Cardiac Repolarization Change of the Dofetilide Sensitivity of Mouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 108. Developmental Changes ofMouse Cardiac Repolarization Change of the Dofetilide Sensitivity of Mouse Cardiac Repolarization Wang et al. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circ Res. 1996 Jul;79(1):79-85.
- 109. + + Cardiac Na /K -ATPases as Important Drug Targets
- 110. + + Gene Expression of Na /K ATPase Subunits
- 111. + + Gene Expression of Na /K ATPase Subunits Cor.At Cardiomyocytes days in culture after Gene symbol thawing Protein 2d 20d ATP1A1 P P Na+/K+-ATPase α1 ATP1A2 P P Na+/K+-ATPase α2 ATP1A3 P P Na+/K+-ATPase α3 ATP1A4 A A Na+/K+-ATPase α4 ATP1B1 P P Na+/K+-ATPase β1 ATP1B2 P P Na+/K+-ATPase β2 ATP1B3 P P Na+/K+-ATPase β3
- 112. + + Na /K ATPase Subunits Homology between Mouse and Human Amino Acid Sequences Na+/K+ ATPase catalytic alpha subunits: ATP1A1 Identities = 963/992 (97%), Positives = 979/992 (98%), Gaps = 0/992 (0%) Identities = 991/1023 (96%), Positives = 1008/1023 (98%), Gaps = 0/1023 (0%) ATP1A2 Identities = 1011/1020 (99%), Positives = 1018/1020 (99%), Gaps = 0/1020 (0%) ATP1A3 Identities = 1001/1005 (99%), Positives = 1003/1005 (99%), Gaps = 0/1005 (0%) Na+/K+ ATPase regulatory beta subunits: ATP1B1 Identities = 285/304 (93%), Positives = 298/304 (98%), Gaps = 1/304 (0%) Identities = 282/302 (93%), Positives = 295/302 (97%), Gaps = 1/302 (0%) ATP1B2 Identities = 282/290 (97%), Positives = 287/290 (98%), Gaps = 0/290 (0%)
- 113. ® Cor.At Cardiomyocytes andPharmacological Studies with the ICR 8000 ® Aurora Biomed
- 114. ® Cor.At Cardiomyocytes andPharmacological Studies with the ICR 8000 ® Aurora Biomed Dr. Sikander Gill
- 115. + ICR 8000 -Rb Uptake Assay
- 116. + ICR 8000 -Rb Uptake Assay Monitoring of cardiac Na+/K+ ATPases
- 117. + ICR 8000 -Rb Uptake Assay Monitoring of cardiac Na+/K+ ATPases Activity
- 118. + ICR 8000 -Rb Uptake Assay Monitoring of cardiac Na+/K+ ATPases Activity Pharmacology
- 119.
- 120. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current:
- 121. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current: PatchXpress® 7000A from MDS-AT
- 122. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current: PatchXpress® 7000A from MDS-AT QPatch® from Sophion
- 123. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current: PatchXpress® 7000A from MDS-AT QPatch® from Sophion Port-a-Patch® and Patchliner® from Nanion
- 124. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current: PatchXpress® 7000A from MDS-AT QPatch® from Sophion Port-a-Patch® and Patchliner® from Nanion I(Ca,L) beta-adrenergic stimulation was revealed
- 125. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current: PatchXpress® 7000A from MDS-AT QPatch® from Sophion Port-a-Patch® and Patchliner® from Nanion I(Ca,L) beta-adrenergic stimulation was revealed For the first time recording of action potentials from primary-like cardiomyocytes were established in the the Port-a-Patch® and Patchliner® from Nanion.
- 126. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current: PatchXpress® 7000A from MDS-AT QPatch® from Sophion Port-a-Patch® and Patchliner® from Nanion I(Ca,L) beta-adrenergic stimulation was revealed For the first time recording of action potentials from primary-like cardiomyocytes were established in the the Port-a-Patch® and Patchliner® from Nanion. hERG and I(Na) blocker effects on action potentials have been revealed recorded with the Port-a-Patch and Patchliner.
- 127. Summary Cor.At® cardiomyocyteswere successsfully applied to automated patch clamp systems from three different companies to analyse cardiac ion current: PatchXpress® 7000A from MDS-AT QPatch® from Sophion Port-a-Patch® and Patchliner® from Nanion I(Ca,L) beta-adrenergic stimulation was revealed For the first time recording of action potentials from primary-like cardiomyocytes were established in the the Port-a-Patch® and Patchliner® from Nanion. hERG and I(Na) blocker effects on action potentials have been revealed recorded with the Port-a-Patch and Patchliner. Cor.At® cells have been validated to be suitable for HTS applications for the analyses of Na+/K+-ATPase activity and pharmacology in the ICR 8000 from Aurora.
- 128.
- 129. Conclusion ® Cor.At cells are primary-like cardiomyocytes predictive and relevant for pharmacological studies.
- 130. Conclusion ® Cor.At cells are primary-like cardiomyocytes predictive and relevant for pharmacological studies. ® Cor.AT cells are suitable for automated electrophysiology and are validated on leading systems
- 131. Conclusion ® Cor.At cells are primary-like cardiomyocytes predictive and relevant for pharmacological studies. ® Cor.AT cells are suitable for automated electrophysiology and are validated on leading systems ® Cor.At cells capable for scalable HTS and HCS applications
- 132. Conclusion ® Cor.At cells are primary-like cardiomyocytes predictive and relevant for pharmacological studies. ® Cor.AT cells are suitable for automated electrophysiology and are validated on leading systems ® Cor.At cells capable for scalable HTS and HCS applications One relevant cell for all information
- 133. Conclusion ® Cor.At cells are primary-like cardiomyocytes predictive and relevant for pharmacological studies. ® Cor.AT cells are suitable for automated electrophysiology and are validated on leading systems ® Cor.At cells capable for scalable HTS and HCS applications One relevant cell for all information ® Cor.At cardiomyocytes are available now.
- 134.
- 135. Acknowledgment MDS Analytical Technologies: Dr. Xin Jiang Dr. Jan Dolzer Dr. James Costantin Dr. David Yamane
- 136. Acknowledgment MDS Analytical Technologies: Dr. Xin Jiang Dr. Jan Dolzer Dr. James Costantin Dr. David Yamane Sophion SA Dr. Rikke Schrøder-Perrier Dr. Morten Sunesen
- 137. Acknowledgment MDS Analytical Technologies: Dr. Xin Jiang Dr. Jan Dolzer Dr. James Costantin Dr. David Yamane Sophion SA Dr. Rikke Schrøder-Perrier Dr. Morten Sunesen Nanion Technologies: Dr. Sonja Stölzle Dr. Niels Fertig Dr. Cecilia Farre Dr. Claudia Haarmann
- 138. Acknowledgment MDS Analytical Technologies: Aurora Biomed: Dr. Xin Jiang Dr. Sikander Gill Dr. Jan Dolzer Sophia Liang Dr. James Costantin Saranna Brugger Dr. David Yamane Sophion SA Dr. Rikke Schrøder-Perrier Dr. Morten Sunesen Nanion Technologies: Dr. Sonja Stölzle Dr. Niels Fertig Dr. Cecilia Farre Dr. Claudia Haarmann
- 139. Acknowledgment MDS Analytical Technologies: Aurora Biomed: Dr. Xin Jiang Dr. Sikander Gill Dr. Jan Dolzer Sophia Liang Dr. James Costantin Saranna Brugger Dr. David Yamane Sophion SA Institute for Neurophysiology, Dr. Rikke Schrøder-Perrier University of Colone: Dr. Morten Sunesen Alexey Kuzmenkin Huamin Liang Prof. Jürgen Hescheler Nanion Technologies: Dr. Sonja Stölzle Dr. Niels Fertig Dr. Cecilia Farre Dr. Claudia Haarmann
- 140. Acknowledgment MDS Analytical Technologies: Aurora Biomed: Dr. Xin Jiang Dr. Sikander Gill Dr. Jan Dolzer Sophia Liang Dr. James Costantin Saranna Brugger Dr. David Yamane Sophion SA Institute for Neurophysiology, Dr. Rikke Schrøder-Perrier University of Colone: Dr. Morten Sunesen Alexey Kuzmenkin Huamin Liang Prof. Jürgen Hescheler Axiogenesis AG: Nanion Technologies: Dr. Heribert Bohlen Dr. Sonja Stölzle Dr. Eugen Kolossov Dr. Niels Fertig Dr. Silke Schwengberg Dr. Cecilia Farre Dr. Andreas Ehlich Dr. Claudia Haarmann Josef Tenelsen Peter Metzger
- 141.
- 142. Acknowledgment North America: www.reachbio.com
- 143. Acknowledgment North America: Special thanks to: Dr. Eric Atkinson Lynn MacIntyre www.reachbio.com
- 144. Acknowledgment North America: Special thanks to: Dr. Eric Atkinson Lynn MacIntyre www.reachbio.com Japan: Dr. Junya Koda Dr. Chie Kodama www.veritastk.com